Panacea Biotec has informed about the press release on its abbreviated new drug application (ANDA) which was submitted under section 505(j) of the Federal Food, Drug and Cosmetic Act (FD&C Act) for Paclitaxel Protein Bound Particles for injectable Suspension, 100mg/vial has been accepted for filing by the US Food and Drug Administration (FDA).
The above information is a part of company’s filings submitted to BSE.
